Cargando…
Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
We report the case of a 19-year-old male who complained of myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, New Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472996/ https://www.ncbi.nlm.nih.gov/pubmed/34579193 http://dx.doi.org/10.3390/vaccines9090956 |
_version_ | 1784574877545529344 |
---|---|
author | Gelbenegger, Georg Cacioppo, Filippo Firbas, Christa Jilma, Bernd |
author_facet | Gelbenegger, Georg Cacioppo, Filippo Firbas, Christa Jilma, Bernd |
author_sort | Gelbenegger, Georg |
collection | PubMed |
description | We report the case of a 19-year-old male who complained of myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, New Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level, and his urinary dipstick tested positive for blood, indicative of acute rhabdomyolysis. Serum creatinine levels were normal. Rhabdomyolysis due to strenuous physical activity was ruled out and further diagnostics excluded an autoimmune cause. Under repeated treatment with intravenous fluid resuscitation (outpatient treatment), his symptoms resolved and peak CK levels of 44,180 U/L returned to almost normal levels within two weeks. Rhabdomyolysis is a rare, potentially fatal vaccine-induced reaction. Further research is needed to better understand the underlying pathomechanism and to investigate whether subcutaneous injection of vaccines may be able to prevent rhabdomyolysis. |
format | Online Article Text |
id | pubmed-8472996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84729962021-09-28 Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination Gelbenegger, Georg Cacioppo, Filippo Firbas, Christa Jilma, Bernd Vaccines (Basel) Brief Report We report the case of a 19-year-old male who complained of myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, New Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level, and his urinary dipstick tested positive for blood, indicative of acute rhabdomyolysis. Serum creatinine levels were normal. Rhabdomyolysis due to strenuous physical activity was ruled out and further diagnostics excluded an autoimmune cause. Under repeated treatment with intravenous fluid resuscitation (outpatient treatment), his symptoms resolved and peak CK levels of 44,180 U/L returned to almost normal levels within two weeks. Rhabdomyolysis is a rare, potentially fatal vaccine-induced reaction. Further research is needed to better understand the underlying pathomechanism and to investigate whether subcutaneous injection of vaccines may be able to prevent rhabdomyolysis. MDPI 2021-08-27 /pmc/articles/PMC8472996/ /pubmed/34579193 http://dx.doi.org/10.3390/vaccines9090956 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Gelbenegger, Georg Cacioppo, Filippo Firbas, Christa Jilma, Bernd Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination |
title | Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination |
title_full | Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination |
title_fullStr | Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination |
title_full_unstemmed | Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination |
title_short | Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination |
title_sort | rhabdomyolysis following ad26.cov2.s covid-19 vaccination |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472996/ https://www.ncbi.nlm.nih.gov/pubmed/34579193 http://dx.doi.org/10.3390/vaccines9090956 |
work_keys_str_mv | AT gelbeneggergeorg rhabdomyolysisfollowingad26cov2scovid19vaccination AT cacioppofilippo rhabdomyolysisfollowingad26cov2scovid19vaccination AT firbaschrista rhabdomyolysisfollowingad26cov2scovid19vaccination AT jilmabernd rhabdomyolysisfollowingad26cov2scovid19vaccination |